JP2012502962A - 肺の炎症および線維症の予防および／または治療のための尿酸レベルを低下させることができる化合物の使用 - Google Patents
肺の炎症および線維症の予防および／または治療のための尿酸レベルを低下させることができる化合物の使用 Download PDFInfo
- Publication number
- JP2012502962A JP2012502962A JP2011527342A JP2011527342A JP2012502962A JP 2012502962 A JP2012502962 A JP 2012502962A JP 2011527342 A JP2011527342 A JP 2011527342A JP 2011527342 A JP2011527342 A JP 2011527342A JP 2012502962 A JP2012502962 A JP 2012502962A
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- lung
- inflammation
- pulmonary
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 219
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 206
- 229940116269 uric acid Drugs 0.000 title claims abstract description 206
- 230000004761 fibrosis Effects 0.000 title claims abstract description 56
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title claims abstract description 11
- 208000005069 pulmonary fibrosis Diseases 0.000 title description 22
- 210000004072 lung Anatomy 0.000 claims abstract description 94
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract description 68
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229960003459 allopurinol Drugs 0.000 claims abstract description 53
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 49
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims abstract description 14
- 230000029142 excretion Effects 0.000 claims abstract description 11
- 230000007170 pathology Effects 0.000 claims abstract description 10
- 230000001363 autoimmune Effects 0.000 claims abstract description 8
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 230000007881 chronic fibrosis Effects 0.000 claims abstract description 6
- 229960003081 probenecid Drugs 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 238000012216 screening Methods 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 12
- 229940005267 urate oxidase Drugs 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 108010089503 Organic Anion Transporters Proteins 0.000 claims description 7
- 102000007990 Organic Anion Transporters Human genes 0.000 claims description 7
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 6
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 108010084837 rasburicase Proteins 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- LLMGYOJUHDRDFJ-UHFFFAOYSA-N 5-(dimethylamino)-9-methyl-2-propylpyrazolo[1,2-a][1,2,4]benzotriazine-1,3-dione;dihydrate Chemical compound O.O.CC1=CC=C2N=C(N(C)C)N3C(=O)C(CCC)C(=O)N3C2=C1 LLMGYOJUHDRDFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims description 2
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229960001671 azapropazone Drugs 0.000 claims description 2
- 229960002529 benzbromarone Drugs 0.000 claims description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 229960000424 rasburicase Drugs 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003329 sulfinpyrazone Drugs 0.000 claims description 2
- 150000008634 thiazolopyrimidines Chemical class 0.000 claims description 2
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 2
- 239000003768 thromboxane synthase inhibitor Substances 0.000 claims description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 94
- 206010061218 Inflammation Diseases 0.000 description 79
- 230000004054 inflammatory process Effects 0.000 description 79
- 239000013078 crystal Substances 0.000 description 77
- 108010006654 Bleomycin Proteins 0.000 description 76
- 229960001561 bleomycin Drugs 0.000 description 75
- 241000699670 Mus sp. Species 0.000 description 66
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 62
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 62
- 108010034143 Inflammasomes Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 32
- 210000000440 neutrophil Anatomy 0.000 description 32
- 230000002950 deficient Effects 0.000 description 29
- 230000001419 dependent effect Effects 0.000 description 28
- 230000019189 interleukin-1 beta production Effects 0.000 description 27
- 238000004519 manufacturing process Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 23
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 20
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 19
- 102100035631 Bloom syndrome protein Human genes 0.000 description 19
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 208000004852 Lung Injury Diseases 0.000 description 18
- 206010069363 Traumatic lung injury Diseases 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 231100000515 lung injury Toxicity 0.000 description 18
- 238000007634 remodeling Methods 0.000 description 18
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 17
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 17
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 17
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 17
- 230000008439 repair process Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 11
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 10
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 102100035904 Caspase-1 Human genes 0.000 description 9
- 108090000426 Caspase-1 Proteins 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 230000004941 influx Effects 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 229960000458 allantoin Drugs 0.000 description 6
- 210000001132 alveolar macrophage Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000005265 lung cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 108700016226 indium-bleomycin Proteins 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 208000037816 tissue injury Diseases 0.000 description 5
- 230000007838 tissue remodeling Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 4
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 229960004238 anakinra Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- -1 1,2,4-triazole compound Chemical class 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 2
- 101000989950 Otolemur crassicaudatus Hemoglobin subunit alpha-A Proteins 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 2
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 230000013932 chemokine (C-X-C motif) ligand 1 production Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- UXTIAFYTYOEQHV-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-2-methoxyaniline;hydron;dichloride Chemical compound [Cl-].[Cl-].C1=C([NH3+])C(OC)=CC(C=2C=C(OC)C([NH3+])=CC=2)=C1 UXTIAFYTYOEQHV-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 101001002629 Mus musculus Interleukin-1 alpha Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010038731 Respiratory tract irritation Diseases 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/62—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving uric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T436/148888—Uric acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305565A EP2165705A1 (en) | 2008-09-18 | 2008-09-18 | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
| EP08305565.7 | 2008-09-18 | ||
| PCT/EP2009/062159 WO2010031859A1 (en) | 2008-09-18 | 2009-09-18 | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502962A true JP2012502962A (ja) | 2012-02-02 |
| JP2012502962A5 JP2012502962A5 (enExample) | 2012-11-01 |
Family
ID=40329393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527342A Pending JP2012502962A (ja) | 2008-09-18 | 2009-09-18 | 肺の炎症および線維症の予防および／または治療のための尿酸レベルを低下させることができる化合物の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8569017B2 (enExample) |
| EP (2) | EP2165705A1 (enExample) |
| JP (1) | JP2012502962A (enExample) |
| CA (1) | CA2737392A1 (enExample) |
| WO (1) | WO2010031859A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200045738A (ko) * | 2018-10-23 | 2020-05-06 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021083278A1 (en) * | 2019-10-29 | 2021-05-06 | Westlake Therapeutics (Hangzhou) Co. Limited | Engineering red blood cells for treating gout and hyperuricemia diseases |
| CA3184151A1 (en) * | 2020-06-29 | 2022-01-06 | Chris Murphy | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
| CN115039737B (zh) * | 2021-08-09 | 2023-07-25 | 北京中医药大学 | 一种建立尿酸盐肾沉积动物模型的方法 |
| KR20230050232A (ko) * | 2021-10-07 | 2023-04-14 | 주식회사 이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030138A2 (en) * | 2003-09-26 | 2005-04-07 | Webb Waring Institute | Methods of modulating inflammatory reactions by modulating xanthine oxidoreductase activity |
| WO2007077261A1 (en) * | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2967535D1 (en) | 1979-11-10 | 1985-11-28 | Siegfried Ag | Xanthinoxydase inhibitors and utilization of benzotriazine derivatives |
| US5021448A (en) | 1990-02-22 | 1991-06-04 | Ciba-Geigy Corporation | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist |
| CA2338665C (en) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| DK1452528T3 (da) | 2001-11-16 | 2008-11-10 | Nippon Chemiphar Co | Xanthinoxidaserinhibitorer |
| BRPI0212775B8 (pt) | 2002-01-28 | 2021-05-25 | Fuji Yakuhin Co Ltd | composto de 1,2,4-triazol e medicamento |
| WO2008144616A1 (en) * | 2007-05-18 | 2008-11-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
| EP2170270B1 (en) * | 2007-06-05 | 2016-01-13 | Paka Pulmonary Pharmaceuticals, Inc. | Compositions for delivering medicaments into the lungs, uses thereof |
-
2008
- 2008-09-18 EP EP08305565A patent/EP2165705A1/en not_active Withdrawn
-
2009
- 2009-09-18 CA CA2737392A patent/CA2737392A1/en not_active Abandoned
- 2009-09-18 EP EP09783212A patent/EP2344149A1/en not_active Withdrawn
- 2009-09-18 US US13/119,363 patent/US8569017B2/en not_active Expired - Fee Related
- 2009-09-18 JP JP2011527342A patent/JP2012502962A/ja active Pending
- 2009-09-18 WO PCT/EP2009/062159 patent/WO2010031859A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030138A2 (en) * | 2003-09-26 | 2005-04-07 | Webb Waring Institute | Methods of modulating inflammatory reactions by modulating xanthine oxidoreductase activity |
| WO2007077261A1 (en) * | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
Non-Patent Citations (1)
| Title |
|---|
| JPN6014006666; Ａｍ Ｊ Ｒｅｓｐｉｒ Ｃｒｉｔ Ｃａｒｅ Ｍｅｄ， ｖｏｌ．１７９， ｐ．９０３-９１３ （２００９） * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200045738A (ko) * | 2018-10-23 | 2020-05-06 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
| KR102133290B1 (ko) | 2018-10-23 | 2020-07-13 | 연세대학교 산학협력단 | 결핵의 예방 또는 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2165705A1 (en) | 2010-03-24 |
| CA2737392A1 (en) | 2010-03-25 |
| US8569017B2 (en) | 2013-10-29 |
| US20110243911A1 (en) | 2011-10-06 |
| WO2010031859A1 (en) | 2010-03-25 |
| EP2344149A1 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gasse et al. | Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis | |
| Du et al. | Saikosaponin a ameliorates LPS-induced acute lung injury in mice | |
| Pendergrass et al. | Sex differences in circulating and renal angiotensins of hypertensive mRen. Lewis but not normotensive Lewis rats | |
| JP4271445B2 (ja) | Ａｏｐ−１遺伝子又はａｏｐ−１の発現減少を伴う疾患の治療方法及び当該疾患治療薬 | |
| Gross et al. | Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease | |
| Zhang et al. | NAD+ administration decreases microvascular damage following cardiac ischemia/reperfusion by restoring autophagic flux | |
| JP2012502962A (ja) | 肺の炎症および線維症の予防および／または治療のための尿酸レベルを低下させることができる化合物の使用 | |
| Wang et al. | VX765 alleviates dextran sulfate sodium-induced colitis in mice by suppressing caspase-1-mediated pyroptosis | |
| Levidiotis et al. | Heparanase inhibition reduces proteinuria in a model of accelerated anti‐glomerular basement membrane antibody disease | |
| RU2667963C1 (ru) | Применение ингибиторов vap-1 для лечения фиброзных болезней | |
| JP2012508247A (ja) | 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割 | |
| Chen et al. | Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis | |
| Hartner et al. | Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA–salt rats | |
| Danielson et al. | Relaxin improves renal function and histology in aging Munich Wistar rats | |
| Wu et al. | Complement C3 deficiency ameliorates aging related changes in the kidney | |
| C Reid et al. | Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system | |
| Duan et al. | Cortistatin protects against septic cardiomyopathy by inhibiting cardiomyocyte pyroptosis through the SSTR2-AMPK-NLRP3 pathway | |
| Souza et al. | Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat | |
| RU2402328C2 (ru) | Применение антагонистов рецептора св1 для получения композиции, пригодной для лечения заболеваний печени | |
| Tofteng et al. | Increased COX‐2 after ureter obstruction attenuates fibrosis and is associated with EP2 receptor upregulation in mouse and human kidney | |
| Wei et al. | Biphasic effects of selective inhibition of transforming growth factor β1 activin receptor-like kinase on LPS-induced lung injury | |
| Kedrah et al. | Effect of the direct renin inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat | |
| Qi et al. | Paeoniflorin alleviated STZ-induced diabetic retinopathy via regulation of the PDI/ADAM17/MerTK pathway | |
| Ezeamuzie et al. | Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)–A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation | |
| EP1882937B1 (en) | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120914 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150519 |